Home › Urothelial (Transitional Cell) Carcinoma › Illinois › Evanston
Urothelial (Transitional Cell) Carcinoma clinical trials in Evanston, IL
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Evanston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
- Illinois Cancer Specialists, Niles · 6 mi away
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- Endeavor Health, Evanston
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RecruitingPhase 2/3
- Research Site, Niles · 6 mi away
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- Orchard Healthcare Research Inc, Skokie · 2 mi away
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Evanston
- Non-Small Cell Lung Cancer22 studies
- Lung Cancer19 studies
- Breast Cancer13 studies
- Acute Myeloid Leukemia11 studies
- Obesity11 studies
- Colorectal Cancer10 studies
- Cancer (all types)9 studies
- Overweight9 studies
- Ulcerative Colitis9 studies
- Prostate Cancer9 studies
- Crohn's Disease9 studies
- Heart Failure8 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.